Evidence map›Paper›PMID 41062323›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Delayed Therapeutic Response to Oral Corticosteroids and Rituximab Leading to Dialysis Independence in a Patient with Treatment-resistant C3 Glomerulonephritis.

Yuki Nakao, Junko Kunieda, Towako Taguchi, Yuki Tanaka, Soichiro Iimori, Fumiaki Ando, Shintaro Mandai, Koichiro Susa, Takayasu Mori, Shotaro Naito and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuki NakaoDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Junko KuniedaDepartment of Pathology, Institute of Science Tokyo Hospital, Japan.
Towako TaguchiDepartment of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Yuki TanakaDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Soichiro IimoriDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Fumiaki AndoDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Shintaro MandaiDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Koichiro SusaDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Takayasu MoriDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Shotaro NaitoDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Kenichi OhashiDepartment of Human Pathology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Eisei SoharaDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Shinichi UchidaDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Yutaro MoriDepartment of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 56-year-old man with nephrotic syndrome was diagnosed with recurrent complement 3 glomerulonephritis (C3GN) without preceding infection. Initial treatment with steroid pulse therapy and oral glucocorticoids failed, and he required hemodialysis due to progressive kidney dysfunction. After rituximab was added, his renal function gradually improved, and dialysis was discontinued. Relapse occurred months later, but combination therapy with steroids and rituximab was effective again. The patient remained dialysis-independent with biannual rituximab infusions. This case illustrates that combining corticosteroids and rituximab may induce remission and preserve the kidney function in relapsing C3GN, even in patients requiring temporary dialysis support.

Indexed as

Adrenal Cortex HormonesComplement C3GlomerulonephritisGlucocorticoidsRenal DialysisAdministration, OralAntibodies, Monoclonal, Murine-DerivedDrug ResistanceDrug Therapy, CombinationHumansMaleMiddle AgedNephrotic SyndromeRituximabTime FactorsTreatment OutcomeAdrenal Cortex HormonesAntibodies, Monoclonal, Murine-DerivedComplement C3GlucocorticoidsRituximabcomplement 3 glomerulonephritiscomplement 3 glomerulopathymembranoproliferative glomerulonephritisrituximab

Identifiers

PMID41062323
PMCPMC13265115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.